Literature DB >> 28591852

Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls.

Erin Kelty1,2, Gary Hulse1.   

Abstract

Aims: To compare morbidity and mortality in opioid dependence patients following the commencement of treatment with the general population.
Methods: Morbidity and mortality in all patients treated with methadone, buprenorphine or implant naltrexone for opioid dependence for the first time between 2001 and 2010 in Western Australia was compared to a cohort of age and gender matched controls using state health records.
Results: Compared to community controls rates of all-cause mortality, hospital admissions and Emergency Department attendances are significantly elevated in opioid dependent persons following the commencement of their first treatment. Not surprisingly, rates of opioid and non-opioid drug poisoning, and intentional self-harm/suicide mortality and hospital admissions were significantly elevated in opioid dependent patients compared with non-dependent controls. However, significant increases in mortality and hospital admissions for conditions which are not generally associated with opioid use were also identified including cardiovascular, respiratory and traffic accidents. Life-time prevalence of both HBV and HCV were significantly elevated in opioid dependent patients compared with non-dependent patients. Conclusions: Even after the commencement of treatment, opioid dependent patients are at a high risk of morbidity and mortality compared with non-dependent age and gender matched controls.

Entities:  

Mesh:

Year:  2018        PMID: 28591852     DOI: 10.1093/pubmed/fdx063

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  1 in total

1.  Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013-2017): a prospective cohort study.

Authors:  Jørn Henrik Vold; Svetlana Skurtveit; Christer Aas; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  BMC Health Serv Res       Date:  2020-07-20       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.